News

June 4, 2019

Trial results demonstrate excellent PVX108 safety profile in patients with prior anaphylaxis and current asthma

June 4, 2019, Melbourne, Victoria – Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for pe...

May 28, 2019

 Data show that PVX108 demonstrates exceptional safety in adults with peanut allergy

May 28, 2019, Melbourne, Victoria – Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy, will present...

February 25, 2019

Melbourne biotech to take its revolutionary peanut allergy treatment to Phase II clinical trials

February 25, 2019, Melbourne, Australia – Aravax, a clinical stage biotechnology company focused on developing the next generation of peanut allergy immunotherapy with advan...

February 14, 2019

February 13, 2019, MELBOURNE, Australia – Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy, will present data from a recently completed Phase 1 clinical trial of PVX108 immunotherapy...

July 25, 2018

2 May 2018, Melbourne, Victoria – Aravax has received an additional investment of $1.9M from the Australian Medical Research Commercialisation Fund (MRCF) to complete the ongoing Phase 1 clinical trial, AVX001, and progress Phase 2 plans for its novel treatment of pean...

Please reload

Archive
Please reload

Aravax


Tel: +61 (0)3 9657 0700
Email: info@aravax.com.au​
Address: Level 9, 31 Queen St

Melbourne, Victoria, 3000

Australia

Contact Us